Barclays PLC Nkarta, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Nkarta, Inc. stock. As of the latest transaction made, Barclays PLC holds 232,566 shares of NKTX stock, worth $569,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares

232,566

Previous 232,566 -0.0%

Holding current value

$569,786

Previous $1.05 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$4.52 - $8.0 $649,108 - $1.15 Million	143,608 Added 161.43%	232,566 $1.05 Million
Q2 2024 Aug 14, 2024	BUY	$5.27 - $10.82 $262,614 - $539,182	49,832 Added 127.36%	88,958 $526,000
Q1 2024 May 15, 2024	SELL	$5.59 - $15.71 $234,852 - $660,024	-42,013 Reduced 51.78%	39,126 $423,000
Q4 2023 Feb 15, 2024	BUY	$1.31 - $6.6 $47,156 - $237,580	35,997 Added 79.74%	81,139 $537,000
Q3 2023 Nov 07, 2023	SELL	$1.39 - $2.29 $461,769 - $760,756	-332,208 Reduced 88.04%	45,142 $63,000
Q2 2023 Aug 03, 2023	SELL	$2.19 - $5.17 $38,756 - $91,493	-17,697 Reduced 4.48%	377,350 $827,000
Q1 2023 May 04, 2023	BUY	$3.37 - $6.3 $26,205 - $48,988	7,776 Added 2.01%	395,047 $1.4 Million
Q4 2022 Feb 13, 2023	SELL	$5.14 - $14.35 $341,296 - $952,840	-66,400 Reduced 14.64%	387,271 $2.32 Million
Q3 2022 Nov 03, 2022	BUY	$12.27 - $18.39 $1.31 Million - $1.96 Million	106,775 Added 30.78%	453,671 $5.97 Million
Q2 2022 Aug 12, 2022	BUY	$7.77 - $19.44 $2.66 Million - $6.66 Million	342,666 Added 8100.85%	346,896 $4.27 Million
Q1 2022 May 16, 2022	BUY	$8.66 - $14.99 $36,631 - $63,407	4,230 New	4,230 $48,000

Others Institutions Holding NKTX

# of Institutions

129

Shares Held

66.5M

Call Options Held

173K

Put Options Held

20K

View Full List

About Nkarta, Inc.

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $119M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

More about NKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account